Organon rises after US FDA clears first biosimilar for breast cancer

Shanghai Henlius Biotech

17/11/2025 11:08

** Shares of healthcare firm Organon OGN.N rise 4.65% to $7.88 premarket

** Co and Shanghai Henlius Biotech say US FDA approves their breast cancer drug Poherdy

** The two companies' Poherdy first biosimilar to rival Roche's ROG.S Perjeta for HER2-positive breast cancer - OGN

** Co says drug to be used with other therapies for advanced or early-stage breast cancer; Organon to market in U.S - OGN

** Poherdy carries warnings for heart issues and birth defects; doctors advised to monitor patients, co says

** Up to last close, stock down ~50% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))